Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA approved PD- L1 inhibitor drug, 840 mg IV, at the beginning and at the end of the two-week time period, concomitantly with FSRT. After this initial two weeks treatment the patients will undergo craniotomy and maximal safe resection as per normal care for a GB. After surgery patients will follow the normal care for glioblastoma in addition to Atezolizumab 840 mg IV q2 weeks for the duration of adjuvant treatment.

NCT Number	NCT05423210
Lead Sponsor	Stony Brook University Collaborators: Genentech, Inc.
Conditions	Glioblastoma Multiforme
Enrollment	12 participants
Start Date	2022-10-25
Primary Completion	2027-08 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2025-12-22